197 related articles for article (PubMed ID: 8588092)
1. Role of T-cells, virus neutralising antibodies and complement-mediated antibody lysis in the immune response against equine herpesvirus type-1 (EHV-1) infection of C3H (H-2k) and BALB/c (H-2d) mice.
Alber DG; Greensill J; Killington RA; Stokes A
Res Vet Sci; 1995 Nov; 59(3):205-13. PubMed ID: 8588092
[TBL] [Abstract][Full Text] [Related]
2. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
[TBL] [Abstract][Full Text] [Related]
3. Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges.
Patel JR; Földi J; Bateman H; Williams J; Didlick S; Stark R
Vet Microbiol; 2003 Mar; 92(1-2):1-17. PubMed ID: 12488066
[TBL] [Abstract][Full Text] [Related]
4. Interactions between equine herpesvirus type 1 and equine herpesvirus type 4: T cell responses in a murine infection model.
Azmi M; Field HJ
J Gen Virol; 1993 Nov; 74 ( Pt 11)():2339-45. PubMed ID: 8245851
[TBL] [Abstract][Full Text] [Related]
5. The mucosal humoral immune response of the horse to infective challenge and vaccination with equine herpesvirus-1 antigens.
Breathnach CC; Yeargan MR; Sheoran AS; Allen GP
Equine Vet J; 2001 Nov; 33(7):651-7. PubMed ID: 11770985
[TBL] [Abstract][Full Text] [Related]
6. Solid matrix-antibody-antigen complexes incorporating equine herpesvirus 1 glycoproteins C and D elicit anti-viral immune responses in BALB/c (H-2K(d)) and C3H (H-2K(k)) mice.
Alber DG; Killington RA; Stokes A
Vaccine; 2000 Nov; 19(7-8):895-901. PubMed ID: 11115713
[TBL] [Abstract][Full Text] [Related]
7. Clinical signs and humoral immune response in horses following equine herpesvirus type-1 infection and their susceptibility to equine herpesvirus type-4 challenge.
Stokes A; Corteyn AH; Murray PK
Res Vet Sci; 1991 Sep; 51(2):141-8. PubMed ID: 1664967
[TBL] [Abstract][Full Text] [Related]
8. Intranasal IgG4/7 antibody responses protect horses against equid herpesvirus-1 (EHV-1) infection including nasal virus shedding and cell-associated viremia.
Perkins G; Babasyan S; Stout AE; Freer H; Rollins A; Wimer CL; Wagner B
Virology; 2019 May; 531():219-232. PubMed ID: 30928700
[TBL] [Abstract][Full Text] [Related]
9. Potential of DNA-mediated vaccination for equine herpesvirus 1.
Ruitenberg KM; Walker C; Wellington JE; Love DN; Whalley JM
Vet Microbiol; 1999 Aug; 68(1-2):35-48. PubMed ID: 10501160
[TBL] [Abstract][Full Text] [Related]
10. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals.
Foote CE; Love DN; Gilkerson JR; Rota J; Trevor-Jones P; Ruitenberg KM; Wellington JE; Whalley JM
Vet Immunol Immunopathol; 2005 May; 105(1-2):47-57. PubMed ID: 15797474
[TBL] [Abstract][Full Text] [Related]
11. One way protection between equid herpesvirus 1 and 4 in vivo.
Edington N; Bridges CG
Res Vet Sci; 1990 Mar; 48(2):235-9. PubMed ID: 2159176
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a live equine herpesvirus-1 (EHV-1) strain C147 vaccine in foals with maternally-derived antibody: protection against EHV-1 infection.
Patel JR; Didlick S; Bateman H
Equine Vet J; 2004 Jul; 36(5):447-51. PubMed ID: 15253088
[TBL] [Abstract][Full Text] [Related]
13. Immunological correlates of vaccination and infection for equine herpesvirus 1.
Goodman LB; Wimer C; Dubovi EJ; Gold C; Wagner B
Clin Vaccine Immunol; 2012 Feb; 19(2):235-41. PubMed ID: 22205656
[TBL] [Abstract][Full Text] [Related]
14. Equine herpesvirus 1 glycoprotein D expressed in E. coli provides partial protection against equine herpesvirus infection in mice and elicits virus-neutralizing antibodies in the horse.
Weerasinghe CU; Learmonth GS; Gilkerson JR; Foote CE; Wellington JE; Whalley JM
Vet Immunol Immunopathol; 2006 May; 111(1-2):59-66. PubMed ID: 16473414
[TBL] [Abstract][Full Text] [Related]
15. Absence of viral antigens on the surface of equine herpesvirus-1-infected peripheral blood mononuclear cells: a strategy to avoid complement-mediated lysis.
van der Meulen KM; Nauwynck HJ; Pensaert MB
J Gen Virol; 2003 Jan; 84(Pt 1):93-97. PubMed ID: 12533704
[TBL] [Abstract][Full Text] [Related]
16. ADCC and complement-dependent lysis as immune mechanisms against EHV-1 infection in the horse.
Stokes A; Wardley RC
Res Vet Sci; 1988 May; 44(3):295-302. PubMed ID: 2841731
[TBL] [Abstract][Full Text] [Related]
17. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC
Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075
[TBL] [Abstract][Full Text] [Related]
18. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies.
Soboll G; Hussey SB; Whalley JM; Allen GP; Koen MT; Santucci N; Fraser DG; Macklin MD; Swain WF; Lunn DP
Vet Immunol Immunopathol; 2006 May; 111(1-2):81-95. PubMed ID: 16549215
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of foals with a modified live, equid herpesvirus-1 gM deletion mutant (RacHΔgM) confers partial protection against infection.
Kydd JH; Hannant D; Robinson RS; Bryant N; Osterrieder N
Vaccine; 2020 Jan; 38(2):388-398. PubMed ID: 31629571
[TBL] [Abstract][Full Text] [Related]
20. An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease.
Schnabel CL; Babasyan S; Rollins A; Freer H; Wimer CL; Perkins GA; Raza F; Osterrieder N; Wagner B
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
